


PART II - STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH, 2020

(INR In Lakhs)

STANDALONE FINANCIALS


Particulars	Quarter Ended		Corp. 3 months ended 31/03/2019	Year Ended	
	3 Months Ended 31/03/2020	Preceding 3 Months Ended 31/12/2019		3/31/2020	3/31/2019
	Audited	Unaudited	Audited	Audited	
I Revenue from Operations	24.20	41.51	62.01	143.19	201.45
II Other Income	5.20	4.98	11.05	15.82	11.05
III Total Revenue (I+II)	29.40	46.49	73.06	159.01	212.49
IV Expenses					
Cost of Material Consumed	3.03	6.31	9.69	22.49	23.00
Employee benefits expense	41.99	25.07	32.58	125.96	136.00
Depreciation and Amortisation expense	0.37	0.24	0.67	1.08	0.94
Other Expenses	25.97	52.23	76.21	198.49	266.74
Total Expenses	71.36	83.85	119.15	348.02	426.68
V Profit/(Loss) from before Exceptional Items and tax (I-IV)	(41.96)	(37.36)	(46.09)	(189.01)	(214.19)
VI Exceptional Items	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(41.96)	(37.36)	(46.09)	(189.01)	(214.19)
VIII Tax Expense:					
Current Tax	-	-	-	-	-
Deferred Tax	-	-	-	-	-
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(41.96)	(37.36)	(46.09)	(189.01)	(214.19)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(41.96)	(37.36)	(46.09)	(189.01)	(214.19)
XIV Other Comprehensive Income					
A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss					
B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	1.85	-	-	1.85	0.63
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(40.11)	(37.36)	(46.09)	(187.16)	(213.56)
XVI Comprehensive Income attributable to Non Controlling Interest	-	-	-	-	-
XVII Comprehensive Income attributable to Owners of the company	(40.11)	(37.36)	(46.09)	(187.16)	(213.56)
XVIII Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
1) Basic	(0.27)	(0.25)	(0.38)	(1.28)	(1.75)
2) Diluted	(0.27)	(0.25)	(0.35)	(1.28)	(1.62)
XIX Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XX Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
1) Basic	(0.27)	(0.25)	(0.38)	(1.28)	(1.75)
2) Diluted	(0.27)	(0.25)	(0.35)	(1.28)	(1.62)
XXI Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,380.87	1,480.87	1,380.87




Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Wednesday, July 29, 2020.
 2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
 3. From effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", applied to all the lease contracts existing on April 01, 2019 using the modified retrospective method. The adoption of the standard did not have any material impact on the financial results of the company for the quarter ended March 31, 2020.
 4. The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. On March 24, 2020, the Indian government announced a strict 21-day lockdown across the country to contain the spread of the virus, which was further extended till June 4, 2020. This pandemic and government response are creating disruption in global supply chain and adversely impacting most of the industries which has resulted in global slowdown.
- The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the year ended March 31, 2020 and has concluded that there is no impact which is required to be recognised in the financial statements. Accordingly, no adjustments have been made to the financial statements.
5. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
 6. The figures of the current quarter ended March 31, 2020 and the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
 7. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
 8. The results are also available on the website of the Company www.drhlsl.com.

For DR HABEEBULLAH LIFE SCIENCES LIMITED




K Krishnam Raju
Executive Chairman (DR: 0087/2020)



Place : Hyderabad
Date: July 29, 2020


DR Habeebullah Life Sciences Limited		
Standalone Statement of Assets and Liabilities		
(INR. in Lakhs)		
Particulars	STANDALONE	
	31/03/2020	31/03/2019
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	2.74	3.83
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	303.23	214.55
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
i Investments	487.06	487.06
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	204.28	202.54
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	-	-
Total Non Current Assets	997.30	907.98
2 Current Assets		
a Inventories	13.11	15.92
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	217.51	221.23
iii Cash and Cash Equivalents	2.35	1.50
iv Bank balances other than above	-	-
v Loans and Advances	134.00	134.00
vi Other financial assets	24.10	9.87
c Current Tax Assets (net)	-	-
d Other Current Assets	304.31	232.42
Total Current Assets	695.40	614.93
Total Assets	1,692.70	1,522.91
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,380.87
b Other Equity	-	-
i Share Warrants	-	50.00
ii Reserves and Surplus	(237.94)	(150.78)
iii Non-Controlling Interests	-	-
Total - Equity	1,242.93	1,280.09




2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	14.50	12.57
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	14.50	12.57
Current Liabilities		
a Financial Liabilities		
i Borrowings	179.15	132.40
ii Trade Payables	30.50	23.99
iii Other Financial Liabilities	-	-
b Other Current Liabilities	223.20	73.10
c Provisions	2.43	0.76
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	435.28	230.25
Total - Equity and Liabilities	1,692.70	1,522.91

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 29/07/2020



K. Krishnam Raju
Executive Chairman (DIN 00874658)



PART II - CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH, 2020

(INR In Lakhs)

Particulars		CONSOLIDATED FINANCIALS			
		Quarter Ended		Year Ended	
		3 Months Ended 31/03/2020	Preceding 3 Months Ended 31/12/2019	3/31/2020	3/31/2019
		Audited	Unaudited	Audited	Audited
I	Revenue from Operations	24.20	41.51	143.19	201.95
II	Other Income	5.20	4.98	15.82	11.05
III	Total Revenue (I+II)	29.40	46.49	159.01	212.99
IV	Expenses				
	Cost of Material Consumed	3.03	6.31	22.49	23.00
	Employee Benefits expense	46.34	29.42	139.96	147.90
	Depreciation and Amortisation expense	0.70	0.31	1.63	1.84
	Other Expenses	27.27	52.30	200.20	275.23
	Total Expenses	77.34	88.34	364.28	447.97
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(47.94)	(41.85)	(205.27)	(235.48)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(47.94)	(41.85)	(205.27)	(235.48)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	(7.11)	-	(7.11)	(2.68)
IX	Profit/(Loss) for the period from Continuing operations (VII-VIII)	(40.83)	(41.85)	(198.16)	(232.80)
X	Profit/(Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/(Loss) for the period from discontinuing operations after tax (X-XI)				
XIII	Profit/(Loss) for the period (IX+XII)	(40.83)	(41.85)	(198.16)	(232.80)
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to Items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to Items that will be reclassified to profit or loss	1.85	-	1.85	0.63
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(38.98)	(41.85)	(196.31)	(232.17)
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	(4.45)	(9.06)
XVII	Comprehensive Income attributable to Owners of the company	(38.98)	(41.85)	(191.86)	(223.11)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.26)	(0.28)	(1.31)	(1.83)
	2) Diluted	(0.26)	(0.28)	(1.31)	(1.69)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)				
	1) Basic	-	-	-	-
	2) Diluted	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.26)	(0.28)	(1.31)	(1.83)
	2) Diluted	(0.26)	(0.28)	(1.31)	(1.69)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,380.87





Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Wednesday, July 29, 2020.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Consolidated Financial Results includes the results of the Company and its Subsidiary - Knsani Bio Sciences Private Limited.
4. The World Health Organization announced a global health emergency because of a new strain of coronavirus ("COVID-19") and classified its outbreak as a pandemic on March 11, 2020. On March 24, 2020, the Indian government announced a strict 21-day lockdown across the country to contain the spread of the virus, which has been further extended till June 4, 2020. This pandemic and government response are creating disruption in global supply chain and adversely impacting most of the industries which has resulted in global slowdown.


The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the year ended March 31, 2020 and has concluded that there is no impact which is required to be recognised in the financial statements. Accordingly, no adjustments have been made to the financial statements.
5. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
6. Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", applied to all the lease contracts existing on April 01, 2019 using the modified retrospective method. The adoption of the standard did not have any material impact on the financial results of the company for the quarter ended March 31, 2020.
7. The figures of the current quarter ended March 31, 2020 and the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
8. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
9. The corresponding previous quarter IV (Q4) ended figures have not been provided as they were not declared in consolidated financial statements for the previous year.
10. The results are also available on the website of the Company www.dihlsl.com.

Place : Hyderabad
Date: July 29, 2020


K Krishnam Raju
Executive Chairman (DIN 00074660)




DR Habeebullah Life Sciences Limited		
Consolidated Statement of Assets and Liabilities		
(INR. in Lakhs)		
Particulars	CONSOLIDATED	
	31/03/2020	31/03/2019
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	13.19	25.97
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	1,899.26	1,776.70
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
i Investments	0.75	0.75
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	204.28	202.54
v Loans	-	-
vi Others	-	-
j Deferred Tax Assets (net)	46.10	38.99
j Other Non Current Assets	-	-
Total Non Current Assets	2,163.57	2,044.95
2 Current Assets		
a Inventories	13.11	15.92
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	217.51	221.23
iii Cash and Cash Equivalents	2.94	2.30
iv Bank balances other than above	-	-
v Loans	94.00	94.00
vi Other financial assets	24.10	9.87
c Current Tax Assets (net)	-	-
d Other Current Assets	305.97	234.05
Total Current Assets	657.65	577.37
Total Assets	2,821.22	2,622.32
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,380.87
b Other Equity	-	-
i Share Warrants	-	50.00
ii Reserves and Surplus	(302.56)	(210.70)
iii Non-Controlling Interests	400.55	405.00
Total - Equity	1,578.86	1,625.17



2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	14.50	12.57
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	14.50	12.57
Current Liabilities		
a Financial Liabilities		
i Borrowings	858.40	791.80
ii Trade Payables	30.50	23.99
iii Other Financial Liabilities		-
b Other Current Liabilities	336.53	168.02
c Provisions	2.43	0.76
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	1,227.86	984.58
Total - Equity and Liabilities	2,821.22	2,622.32

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju



Place: Hyderabad
Date: 29/07/2020


K. Krishnam Raju
Executive Chairman (DIN 00874650)


DR HABEEBULLAH LIFE SCIENCES LIMITED
 Sy. No. 36, Chintalmet X Roads, Upparapally, Attapur
 Rajendra Nagar Mandal HYDERABAD Hyderabad TS 500048 IN
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2020

PARTICULARS	Year ended 31-03-2020 Amount in Rs.	Year ended 31-03-2019 Amount in Rs.
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(18,716,742)	(21,355,225)
<u>Adjustment for:</u>		
Depreciation and Amortisation	108,374	94,493
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(18,608,368)	(21,260,732)
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	371,574	6,617,080
(Increase)/ Decrease in Short Term Loans and Advances	-	(6,400,000)
(Increase)/ Decrease in other Current Assets	(7,189,718)	(18,581,288)
(Increase)/ Decrease in other other financial Assets	(1,423,643)	(986,676)
(Increase)/ Decrease in Inventories	280,777	(640,168)
Increase / (Decrease) in Trade Payables	650,690	1,778,462
Increase/ (Decrease) in Other current liabilities	15,010,500	4,898,983
Increase/ (Decrease) in Current Provisions	166,566	43,813
Change in Working Capital	7,866,746	(13,269,794)
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	(173,448)	(729,214)
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	192,298	664,833
Changes in non current assets and liabilities	18,850	(64,381)
<u>Cash Generated From Operations</u>	(10,722,772)	(34,594,907)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(10,722,772)	(34,594,907)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(8,867,046)	(12,568,450)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(8,867,046)	(12,568,450)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) In Share Capital	15,000,000	30,750,000
Increase / (Decrease) In Borrowings	4,675,000	13,240,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	19,675,000	43,990,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	85,182	(3,173,357)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	149,880	3,323,237
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	235,062	149,880

As per our report of even date
 for MSKA & Associates
 Chartered Accountants
 Firm Registration No: 105047W

for and on behalf of the
 for DR HABEEBULLAH LIFE SCIENCES LIMITED


 K. Krishnam Raju
 Whole-time Director & Chairman
 DIN: 00874650



Place: Hyderabad
 Date : 29-07-2020


DR HABEEBULLAH LIFE SCIENCES LIMITED
2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upparapally, Attapur
Rajendra Nagar Mandal, Hyderabad 500048, Telangana State, INDIA


CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2020

PARTICULARS	Year ended 31-03-2020 Amount In Rs.	Year ended 31-03-2019 Amount In Rs.
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(20,527,312)	(23,547,617)
<u>Adjustment for:</u>		
Depreciation and Amortisation	163,064	184,413
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(20,364,248)	(23,363,204)
<u>Movements in Working Capital::</u>		
(Increase) / Decrease in trade receivables	371,574	6,617,080
(Increase) / Decrease in Short term Loans and Advances	-	(2,400,000)
(Increase)/Decrease in other financial assets Assets	(1,423,643)	(986,676)
(Increase)/Decrease in other Current Assets	(7,192,416)	(22,706,458)
(Increase) / Decrease in Inventories	280,778	(640,168)
Increase / (Decrease) in Trade Payables	650,689	1,778,462
Increase/(Decrease) in Other current liabilities	16,851,318	12,061,146
Increase/(Decrease) in Current Provisions	166,565	43,813
Change in Working Capital	9,704,864	(6,232,801)
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	(173,448)	(729,214)
(Decrease)/Increase in Long Term Provisions	377,157	728,258
Changes in non current assets and liabilities	203,709	(956)
<u>Cash Generated From Operations</u>	(10,455,675)	(29,596,961)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(10,455,675)	(29,596,961)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work in progress	(11,139,901)	(15,501,218)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(11,139,901)	(15,501,218)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	15,000,000	30,750,000
Increase / (Decrease) in Borrowings	6,660,000	11,130,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	21,660,000	41,880,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	64,424	(3,218,179)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	229,988	3,448,167
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	294,412	229,988

As per our report of even date
for MSKA & Associates
Chartered Accountants
Firm Registration No: 105047W

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED


K. Krishnam Raju
Whole-time Director & Chairman
DIN: 00874650



Place: Hyderabad
Date : 29-07-2020

Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**To the Board of Directors of Dr Habeebullah Life Sciences Limited****Report on the Audit of Standalone Financial Results****Opinion**

We have audited the accompanying standalone annual financial results of **Dr Habeebullah Life Sciences Limited** (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2020 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other financial information of the Company for the year ended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The Statement include the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our Opinion is not modified in respect of the above matter.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Ananthakrishnan Govindan

Partner

Membership No. 205226

UDIN: 20205226AAAAFY9066

Place: Hyderabad

Date: July 29, 2020

Independent Auditor's Report on Quarterly Consolidated Financial Results and Year to Date Consolidated Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**To the Board of Directors of Dr Habeebullah Life Sciences Limited [Holding Company]****Report on the Audit of Consolidated Financial Results****Opinion**

We have audited the accompanying consolidated annual financial results of **Dr Habeebullah Life Sciences Limited** (hereinafter referred to as the 'Holding Company') and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), for the quarter and year ended March 31, 2020, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditor on separate audited financial statements, of the subsidiary, the aforesaid Statement:

(i) include the annual financial results of the following entity

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net loss and other financial information of the Group for the year ended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities



for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors’ Responsibilities for the Consolidated Financial Results


This Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

1. The Statement include the audited Financial Results of aforesaid subsidiary, whose Financial Statements reflect Group's share of total assets (before consolidation adjustment) of Rs. 16,55,57,682 as at March 31, 2020, Group's share of total revenue (before consolidation adjustment) is Nil and Group's share of total net loss after tax (before consolidation adjustment) of Rs. 914,700 for the year ended March 31,2020 as considered in the Statement, which have been audited by another independent auditors. The independent auditors' reports on financial statements of this subsidiary have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
2. The Statement include the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No. 105047W



Ananthakrishnan Govindan

Partner

Membership No.: 205226

UDIN: 20205226AAAAFZ2199

Place: Hyderabad

Date: July 29, 2020

To,

Date: 29.07.2020

1.) BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

2.) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor, Plot No. C62, Opp. Trident Hotel,
Bandrakurla Complex, Bandra (E), Mumbai-400098

3.) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanad College,
Panjara Pole, Ambawadi, Ahmedabad - 380015

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Scrip Code - 539267

I, K.KrishnamRaju, Whole-Time Director of DrHabeebullah Life Sciences Ltd hereby declare that, the Statutory Auditors of the company M/s. MSKA& Associates., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2020, Standalone and Consolidated.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide Circular No. CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,

For DrHabeebullah Life Sciences Ltd



K.KrishnamRaju
Whole-Time Director
(DIN: 00874650)

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198.

Email: cs@drhlsl.com, info@drhlsl.com, pcproductsindia@gmail.com

Contact No.: 040 - 2970 3333, +91 9030057370.

Website : www.drhlsl.com